Liquidia Says FDA Granted Tentative Approval Of YUTREPIA (Treprostinil) Inhalation Powder To Treat Adults With Pulmonary Arterial Hypertension And Pulmonary Hypertension Associated With Interstitial Lung Disease

Author: Benzinga Newsdesk | August 19, 2024 06:01am

Tentative approval indicates that YUTREPIA has met all regulatory standards for quality, safety and efficacy required for approval in the United States but must await the expiration of regulatory exclusivity of a competing product before final approval can be granted.

Liquidia remains committed to addressing the unmet needs of PAH and PH-ILD patients and will seek final approval of YUTREPIA as early as possible.

Posted In: LQDA